;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Alios raises $41 million in series B

    Viral disease play Alios BioPharma Inc. (South San Francisco, Calif.) raised $41 million in a series B round led by a new undisclosed investor. All of the company's existing investors -- Novo Ventures; SR One; Roche …

    Published on 4/7/2014
  • FINANCIAL NEWS: Deerfield launches $1.6 billion fund

    Deerfield Management launched Deerfield Private Design Fund III with about $1.6 billion. The fund will invest in private and public companies across all stages of development in the biotech, pharmaceutical, medical …

    Published on 4/7/2014
  • FINANCIAL NEWS: Immunosequencing play Adaptive raises $105 million

    Adaptive Biotechnologies Corp. (Seattle, Wash.) raised $105 million from Viking Global Investors. Adaptive said $5 million of the funds will close out a $20 million series C round, with the balance comprising a series D…

    Published on 4/7/2014
  • FINANCIAL NEWS: Pacira planning $100 million follow-on

    Pain company Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) proposed late Monday to raise $100 million in a follow-on underwritten by Jefferies; Barclays Capital; and BofA Merrill Lynch. Pacira markets Exparel for …

    Published on 4/7/2014
  • FINANCIAL NEWS: Vital sets IPO range

    Liver disease company Vital Therapies Inc. (San Diego, Calif.) amended its IPO on NASDAQ and now plans to sell 4.5 million shares at $13-$15. At the $14 midpoint, the company would raise $63 million and be valued at $…

    Published on 4/7/2014
  • FINANCIAL NEWS: IMS Health raises $1 billion in IPO

    IMS Health Holdings Inc. (NYSE:IMS) raised $1 billion through the sale of 52 million shares at $20 in an IPO. The price values the company at $6.6 billion. The offering was underwritten by 17 banks. IMS shareholders …

    Published on 4/4/2014
  • FINANCIAL NEWS: Intercept, Exact Sciences price follow-ons

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Exact Sciences Corp. (NASDAQ:EXAS) both raised money in follow-ons on Friday. Intercept raised $192 million through the sale of 600,000 shares at $320. BofA Merrill Lynch…

    Published on 4/4/2014
  • FINANCIAL NEWS: Catalyst raises $25 million in follow-on

    Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) raised $25 million through the sale of 11.3 million shares at $2.21 in a follow-on underwritten by Piper Jaffray; Roth Capital Partners; and H.C. Wainwright. Catalyst …

    Published on 4/3/2014
  • FINANCIAL NEWS: Lumena files for IPO

    Lumena Pharmaceuticals Inc. (San Diego, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Citigroup; Cowen; and Leerink. The offering comes on the heels of a $45 million series B round that …

    Published on 4/3/2014
  • FINANCIAL NEWS: Quotient amends IPO

    Transfusion diagnostics company Quotient Ltd. (Penicuik, U.K.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $14-$16. At the $15 midpoint, the company would raise $75 million and be valued at $215.…

    Published on 4/3/2014
  • FINANCIAL NEWS: Venaxis raises $20 million in follow-on

    Venaxis Inc. (NASDAQ:APPY) raised $20 million through the sale of 8.3 million shares at $2.40 in a follow-on underwritten by Canaccord and Craig-Hallum Capital. Venaxis proposed the offering late Wednesday, when its …

    Published on 4/3/2014
  • FINANCIAL NEWS: Celgene increasing Acceleron stake

    Orphan disease company Acceleron Pharma Inc. (NASDAQ:XLRN) jumped $4.46 (13%) to $38.33 on Wednesday after disclosing in an SEC filing that partner Celgene Corp. (NASDAQ:CELG) is increasing its stake in Acceleron to …

    Published on 4/2/2014
  • FINANCIAL NEWS: Exact Sciences planning $125 million follow-on

    Diagnostic company Exact Sciences Corp. (NASDAQ:EXAS) proposed late Wednesday to raise $125 million in a follow-on underwritten by Jefferies; Goldman Sachs; Baird; William Blair; and Canaccord. Last week, the Molecular …

    Published on 4/2/2014
  • FINANCIAL NEWS: MannKind soars on Afrezza vote

    MannKind Corp. (NASDAQ:MNKD) jumped $2.97 (74%) to $6.99 on Wednesday after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted on Tuesday that the company's Afrezza is safe and effective to treat Type I …

    Published on 4/2/2014
  • FINANCIAL NEWS: Oncodesign, Genomic Vision price French IPOs

    Oncodesign S.A. (Euronext:ALONC) and Genomic Vision S.A. (Euronext:GV) both raised money in IPOs on Euronext Paris. Oncodesign raised EUR 12.2 million ($16.8 million) through the sale of 1.7 million new shares at EUR 7.…

    Published on 4/2/2014
  • FINANCIAL NEWS: Scynexis amends IPO again

    Scynexis Inc. (Research Triangle Park, N.C.) again amended its IPO and now plans to sell 7.3 million shares at $7-$8. At the $7.50 midpoint, the company would raise $55 million and be valued at $141.2 million. Last …

    Published on 4/2/2014
  • FINANCIAL NEWS: Foresite closes second fund with $300 million

    Foresite Capital Management closed Foresite Capital Fund II with $300 million. The firm, which closed its first fund with $100 million in January 2013, invests $10-$100 million in late-stage companies across the …

    Published on 4/1/2014
  • FINANCIAL NEWS: Intarcia raises $200 million

    Intarcia Therapeutics Inc. (Boston, Mass.) raised $200 million in a series DD round led by new investor RA Capital. New investors Franklin Templeton LLC; Fred Alger Management; and Quilvest also participated along with …

    Published on 4/1/2014
  • FINANCIAL NEWS: Intercept proposes follow-on

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) proposed to sell 600,000 shares in a follow-on underwritten by BofA Merrill Lynch; Citigroup; Goldman Sachs; Deutsche Bank; BMO Capital Markets; Needham; Oppenheimer; Wedbush…

    Published on 4/1/2014
  • FINANCIAL NEWS: Cancer play Cerulean sets IPO terms

    Cerulean Pharma Inc. (Cambridge, Mass.) amended its IPO on NASDAQ and now plans to sell 5 million shares at $11-$13. At the $12 midpoint, the company would raise $60 million and be valued at $171.7 million. Cerulean …

    Published on 3/31/2014
  • FINANCIAL NEWS: SkyePharma to raise up to L112.1 million

    Drug delivery company SkyePharma plc (LSE:SKP) proposed to raise up to L112.1 million ($186.5 million) through the sale of 58.7 million shares at 191p in a placing and open offer. The price is a 5% discount to …

    Published on 3/31/2014
  • FINANCIAL NEWS: Endocyte raises $94.5 million in follow-on

    Endocyte Inc. (NASDAQ:ECYT) raised $94.5 million through the sale of 4.5 million shares at $21 in a follow-on underwritten by Credit Suisse; Citigroup; Cowen; RBC Capital Markets; Baird; Wedbush PacGrow; and Roth …

    Published on 3/28/2014
  • FINANCIAL NEWS: Applied Genetic raises $50 million in IPO

    Rare ophthalmic disease company Applied Genetic Technologies Corp. (NASDAQ:AGTC) raised $50 million in an IPO through a bumped-up number of shares below its price range. The company sold 4.2 million shares at $12, which…

    Published on 3/27/2014
  • FINANCIAL NEWS: Cancer play Syndax files for IPO

    Syndax Pharmaceuticals Inc. (Waltham, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by Deutsche Bank; Jefferies; JMP Securities; and Wedbush PacGrow. Next month, the ECOG-ACRIN Cancer Research…

    Published on 3/27/2014
  • FINANCIAL NEWS: Horizon up on trading debut

    Cell line and assay supplier Horizon Discovery Group plc (LSE:HZD) was up 34.5p (19%) to 214.5p on its first day of trading on the London Stock Exchange's AIM on Thursday. On Monday, the company raised L40 million ($66 …

    Published on 3/27/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993